Objective: To identify converging themes from the neurodevelopmental hypothesis of
schizophrenia and the pathophysiology of diabetic pregnancy and to examine mechanisms by …

A decade of clinical experience and research indicates that compliance behaviour has only
marginally improved since the introduction of second generation antipsychotic drugs. …

Schizophrenia is a disabling, chronic psychiatric disorder that poses numerous challenges
in its management and consequences. It extols a significant cost to the patient in terms of …

In a research study aimed at examining the alterations in dopaminergic function in schizophrenia,
the authors identified a surreptitious case scenario which provided new insights into …

In 1997, we published a review in Pharmaco Economics about quality of life (QOL) measurement
in patients with schizophrenia. The objective of this article is to provide an update, as …

Objectives: Neuroleptic drugs induce psychological side effects such as dysphoria, cognitive
impairment, and loss of motivation. These side effects were largely underrecognized and …

… a recent study, we reported that the cost utility approach in schizophrenia, although feasible,
requires further research to resolve several methodological difficulties (Awad and Voruganti …

Schizophrenia is a long-term disabling illness that affects approximately 1% of the population.
Its course is generally chronic with acute psychotic exacerbations that may require …

Estimation of quality of life is important to the study of the pharmacoeconomics of schizophrenia.
The subject has gained popularity among policymakers, clinicians, and patients and …

Schizophrenia is a chronic disabling illness that affects about 1 % of the population. It is a
heterogenous disorder with variable aetiological. prognostic and treatment response patterns. …